Objective response rate

What it is

Objective response rate (ORR) is the percentage of patients in a cancer trial whose measurable tumours shrink enough to qualify as a complete response or partial response by formal criteria such as RECIST 1.1. The key number is that ORR counts complete response (CR) plus partial response (PR), and it does not include stable disease. In solid-tumour studies, ORR is usually reported as a percentage, for example 25% if 25 out of 100 evaluable patients have CR or PR. It is commonly used in phase 1 and phase 2 oncology trials because it can be measured earlier than overall survival.

ORR is a trial endpoint, not a treatment by itself. It tells researchers how many patients had a measurable reduction in tumour burden after treatment. In many studies, scans such as CT or MRI are reviewed using standardised rules. For most solid tumours, the most widely used framework is RECIST 1.1, although some cancers use disease-specific systems such as RANO for glioblastoma or immune-related response criteria in immunotherapy research.

A simple way to think about ORR is:

Response category	Counts in ORR?	General meaning
Complete response (CR)	Yes	All detectable target lesions disappear
Partial response (PR)	Yes	Tumour burden decreases by the required amount
Stable disease (SD)	No	Cancer has not shrunk enough for PR and has not grown enough for progression
Progressive disease (PD)	No	Cancer has grown or new lesions appeared

Because ORR focuses on tumour shrinkage, it is most useful when shrinkage itself is clinically meaningful, such as relieving symptoms, reducing tumour bulk, or showing strong antitumor activity in a setting where few treatments work.

How it works

ORR is calculated from patients who have measurable disease at baseline and at least one valid post-treatment assessment, depending on the trial protocol. The basic formula is:

1. Count the number of patients with CR or PR.
2. Divide by the number of evaluable patients.
3. Express the result as a percentage.

For example, if 8 patients have PR and 2 have CR among 40 evaluable patients, the ORR is 10/40, or 25%.

In RECIST 1.1, a partial response generally means at least a 30% decrease in the sum of diameters of target lesions from baseline, while progressive disease generally means at least a 20% increase from the smallest recorded sum, with an absolute increase requirement, or the appearance of new lesions. A complete response means disappearance of all target lesions, with additional rules for lymph nodes. Some trials require responses to be confirmed on a later scan, which makes ORR more reliable. Others may report unconfirmed ORR, especially in early-phase studies.

Several details can change the reported ORR:

• Who is assessed: all treated patients versus only response-evaluable patients.
• Who reads the scans: local investigators versus blinded independent central review.
• When scans are done: shorter or longer intervals can affect detection of response.
• Which criteria are used: RECIST, RANO, lymphoma criteria, or immune-adapted criteria.

These differences matter when comparing one trial with another.

Evidence and uses

ORR is widely used in oncology drug development, especially for advanced cancers and single-arm studies. Regulators have sometimes accepted high ORR, particularly when responses are durable and treatment options are limited, as part of the evidence supporting accelerated or conditional approval. This is more likely when the observed responses are clearly better than what would be expected historically.

ORR can be helpful because it is:

• available earlier than overall survival data,
• easier to measure objectively than symptom improvement alone,
• useful in rare cancers or biomarker-defined subgroups where large randomised trials are difficult.

At the same time, ORR is not the same as living longer or being cured. A treatment can improve ORR without clearly improving overall survival or quality of life. This is one reason oncology trials often also report:

Endpoint	What it measures
ORR	Percentage with CR or PR
Duration of response (DoR)	How long the response lasts
Progression-free survival (PFS)	Time until cancer grows or patient dies
Overall survival (OS)	Time until death from any cause
Disease control rate (DCR)	CR + PR + stable disease

The research literature shows that the value of ORR depends on context. In some diseases, a high ORR is associated with meaningful benefit. In others, the link between ORR and survival is weaker. The association can also differ by drug class. Cytotoxic chemotherapy, targeted therapy, and immunotherapy may produce different response patterns. For example, immunotherapy can sometimes cause delayed responses or atypical imaging changes, which means standard ORR may not capture the full picture.

For patients and families in India reading trial results, ORR is often one of the first numbers highlighted in conference presentations, journal abstracts, and hospital discussions. It is useful, but it should be read alongside DoR, PFS, OS, side effects, and whether the study population resembles the real-world patient being considered.

Diagnosis / how it's measured

ORR is measured through scheduled tumour assessments, usually imaging. The process often includes:

1. Baseline measurement of target lesions before treatment.
2. Repeat scans after a defined number of weeks or cycles.
3. Classification of each patient's best overall response.
4. Calculation of the percentage with CR or PR.

Most solid-tumour trials use RECIST 1.1. Important measurement issues include lesion selection, consistency of imaging technique, and whether non-target lesions or new lesions appear. In brain tumours, criteria such as RANO may also consider steroid use and neurological status, not just scan size.

When reading a paper, it helps to check these points:

• Was ORR confirmed on a later scan?
• Was it assessed by investigator or independent central review?
• What was the confidence interval around the ORR?
• Were all enrolled patients included in the analysis?
• How long was the median duration of response?

Confidence intervals matter because a reported ORR of 20% in a small study may be much less certain than the same ORR in a large study.

When to see a clinician

Ask your oncologist or trial team for help interpreting ORR if you are comparing treatments or considering a clinical trial. This is especially important if the headline result emphasises tumour shrinkage but does not clearly report survival, symptom benefit, or toxicity.

Useful questions include:

• Does this ORR apply to my cancer type and stage?
• Were the responses durable?
• Did patients actually feel better or live longer?
• How do the side effects compare with the likely benefit?
• Is this result from a randomised trial or a single-arm study?

A clinician can also explain whether a response endpoint is appropriate for your disease. In some cancers, stable disease for many months may be very meaningful even if ORR is low.

Limitations and open questions

ORR is important, but it has limits. It does not capture stable disease, symptom relief, or long-term survival on its own. It can also be affected by scan timing, response criteria, and reader variability. Cross-trial comparisons are risky because patient populations and methods often differ.

Evidence is also mixed on how well ORR predicts overall survival across all cancers and treatments. The relationship is stronger in some settings than others. For immunotherapy and some brain tumours, standard response frameworks may miss atypical but clinically relevant benefit.

Another open question is how best to integrate ORR with newer tools such as circulating tumour DNA, functional imaging, and patient-reported outcomes. These may improve how treatment benefit is judged in the future, but they have not replaced standard response assessment. For now, ORR is best viewed as one useful piece of evidence rather than a complete answer about how well a cancer treatment works.